The concern of generic rivalry has repeatedly loomed above copyright’s famous drug, Viagra, sparking questions about the future of similar medicinal holdings. While first years saw substantial gains, the exclusivity expiration has opened the way for less expensive copies, potentially diminishing revenue and creating a significant risk for investo